Company news
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) news
Regeneron Pharmaceuticals, Inc. news releases on 6ix. Latest, Jul 29, 2020: BARDA Procures Regeneron's REGN-EB3 Investigational Ebola Treatment for National…
Press releases — page 8
BARDA Procures Regeneron's REGN-EB3 Investigational Ebola Treatment for National Preparedness
July 28, 2020
Regeneron to Report Second Quarter 2020 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2020
July 7, 2020
Regeneron Announces Manufacturing and Supply Agreement for BARDA and U.S. Department of Defense for REGN-COV2 Anti-Viral Antibody Cocktail
July 6, 2020
Regeneron Announces Start of REGN-COV2 Phase 3 COVID-19 Prevention Trial in Collaboration with National Institute of Allergy and Infectious Diseases (NIAID)
July 5, 2020
Regeneron and Sanofi Provide Update on Kevzara® (sarilumab) Phase 3 U.S. Trial in COVID-19 Patients
July 1, 2020
Regeneron Announces the 2020 Winners of the Regeneron Prize for Creative Innovation
June 21, 2020
FDA Approves New Dupixent® (dupilumab) Pre-filled Pen Designed to Support More Convenient Self-Administration
June 18, 2020
Regeneron Begins First Clinical Trials of Anti-Viral Antibody Cocktail REGN-COV2 for the Treatment and Prevention of COVID-19
June 10, 2020
Regeneron Announces Virtual-Only Format for 2020 Annual Meeting of Shareholders
June 7, 2020
Regeneron Announces Upcoming Investor Conference Presentations
June 4, 2020
Regeneron and Intellia Therapeutics Expand Collaboration to Develop CRISPR/Cas9-Based Treatments
May 31, 2020
Regeneron Completes Secondary Offering of Common Stock Held by Sanofi
May 28, 2020
Regeneron Announces Pricing of Secondary Offering of its Common Stock Held by Sanofi
May 25, 2020
Regeneron Announces Secondary Offering of its Common Stock Held by Sanofi and $5 Billion Stock Repurchase
May 24, 2020
Regeneron and Colorado Center for Personalized Medicine Announce Major New Human Genetics Research Collaboration
May 10, 2020
Regeneron Reports First Quarter 2020 Financial and Operating Results
May 4, 2020
Regeneron and Sanofi Provide Update on U.S. Phase 2/3 Adaptive-Designed Trial of Kevzara® (sarilumab) in Hospitalized COVID-19 Patients
April 26, 2020
FDA Accepts for Priority Review Biologics License Application for REGN-EB3 to Treat Ebola
April 15, 2020
Regeneron and Zai Lab Announce Regional Strategic Collaboration for REGN1979 (CD20xCD3 Bispecific Antibody)
April 7, 2020
Regeneron Finalizes Praluent® (alirocumab) Restructuring and Updates Accounting Presentation
April 5, 2020
Dupixent® (dupilumab) Phase 3 Data at Revolutionizing Atopic Dermatitis Conference Show Significant Improvement in Severe Atopic Dermatitis for Children Aged 6 to 11 Years
April 2, 2020
Regeneron Announces American College of Cardiology Presentation of Positive Phase 3 Evinacumab Results in Patients with Severe Inherited Form of High Cholesterol
March 29, 2020